BRIGHT MINDS BIOSCIENCES INC.
Business
BRIGHT MINDS BIOSCIENCES INC. develops innovative therapeutics to treat severe neurological and psychiatric disorders, focusing on novel serotonergic compounds. The company’s main offerings are new chemical entities and highly selective serotonergic agonists, including lead programs such as BMB-101 and preclinical candidates like BMB-105. Its operations are organized around discovery and preclinical research, clinical development (Phase 1–2/3 trials), and strategic collaborations. The company advances its therapies through clinical trials, research partnerships, and capital markets activities, including U.S. regulatory filings and distribution channels.
Summary from filing dated 2025-12-23
Financials
Latest annual snapshot (FY2025, period end 2025-09-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-12.23M |
| Total assets | $84.42M |
| Total liabilities | $2.38M |
| Stockholders' equity | — |
| Operating cash flow | — |